Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Valeant Pharmaceuticals Intl (NYSE: VRX)

$9.02 USD $0.42 (4.88%)
Last Price $9.02
Net Change $0.42 (4.88%)
Bid $0
Ask Price $0
Open Price $8.56
Previous Close Price $8.6
High Price $9.06
Low Price $8.5
Number of Trades 30,391
Volume 12,658,333
Fifty Two Week High $38.5 (2016-05-03)
Fifty Two Week Low $8.31 (2017-04-24)
Average Daily Volume 18,219,236
Share Outstanding 347,850 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $1.26 (2017-02-28)
2nd Quarter Earnings $1.55 (2016-11-08)
3nd Quarter Earnings $1.4 (2016-08-09)
4th Quarter Earnings $1.27 (2016-06-07)
PE Ratio $1.55
EPS Growth $-27.24
Recent Earnings $1.26
Annual EPS $5.48
Last Quarter EPS $
Market Capitalization $3.14B
Insider Shareholders % 0.0587%
Annual Revenue $0B
No. Shares Outstanding 347,850
Inst. Shareholder % 57.39%
Annual Net Income $0B
TTM Net Profit Margin $446.28
1-Year Return -75.54%
3-Year Return -93.56%
5-Year Return -84.6%
5-Year Revenue Growth 292.7%
5-Year Earnings Growth 100.37%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD -27.24%
Dividends per Share $1
Stock Split Ratio 2-1
Beta -0.16
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.

Today's Valeant Pharmaceuticals Stock Update

Here we've put together some of the most important Valeant Pharmaceuticals stock numbers for you. That includes recent closing price, 52-week highs and lows, and more great information for investors, as of April 25, 2017. First we'll look at where VRX stock ended the last trading session: $8.60. Valeant Pharmaceuticals shares went up 1.06% or $0.09 from the previous day's close. So where does that put Valeant Pharmaceuticals stock relative to the past year of prices? The Valeant Pharmaceuticals stock price is at a lower price than it was last year at this time, with the stock price having slipped 76.10%.

BREAKING: How a 26(f) Program Can Save Your Retirement

The Valeant Pharmaceuticals stock price 52-week high is $38.50. That was hit on 5/03/2016. The VRX stock 52-week low is $8.31, reached on 4/24/2017. Another number to look at - VRX trading volume yesterday was 28,061,900. That's higher than Valeant Pharmaceuticals stock's average daily trading volume of 15,671,070. The market cap of Valeant Pharmaceuticals is 2,991,510,000. That means Valeant Pharmaceuticals has a mid-size market cap, because it's been 2 billion and 10 billion. As of April 1, 2016, the company with the biggest market cap of all publicly traded companies is Apple.

TRENDING: The Best Stocks to Buy Now

The current P/E (price/earnings) ratio of Valeant Pharmaceuticals stock is 1.73. That's not as high as the March 2016 S&P 500 P/E ratio of about 23. To really gauge if this stock's P/E is high or low, you should compare VRX to other companies in the same industry. The current EPS (earnings per share) of VRX is -6.92. Beta - how closely the stock trades with the overall market, with a beta of 1 meaning it trades in step with the broader index -- for Valeant Pharmaceuticals is -0.16. Valeant Pharmaceuticals stock does not pay a dividend right now. Most stocks considered "dividend stocks" have a yield of 2% or more. Money Morning gives you Valeant Pharmaceuticals stock news daily. We publish new info on VRX and dozens of other key companies we're watching now, every day, so investors will never miss an opportunity. As always, our content is free.

UP NEXT: These Are the Top 5 Marijuana Stocks to Watch in 2017 - Don't Miss This Sector's Staggering Profit Potential

Click here to read more stories